Compare BWMX & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWMX | CMPS |
|---|---|---|
| Founded | 1995 | 2020 |
| Country | Mexico | United Kingdom |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 612.0M | 662.5M |
| IPO Year | N/A | 2020 |
| Metric | BWMX | CMPS |
|---|---|---|
| Price | $18.56 | $6.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $24.17 | $16.86 |
| AVG Volume (30 Days) | 116.2K | ★ 1.4M |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | ★ 8.51% | N/A |
| EPS Growth | ★ 15.49 | N/A |
| EPS | ★ 1.49 | N/A |
| Revenue | ★ $775,128,445.00 | N/A |
| Revenue This Year | $2.99 | N/A |
| Revenue Next Year | $4.64 | N/A |
| P/E Ratio | $12.22 | ★ N/A |
| Revenue Growth | ★ 3.60 | N/A |
| 52 Week Low | $7.00 | $2.25 |
| 52 Week High | $19.79 | $8.20 |
| Indicator | BWMX | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 69.56 | 51.17 |
| Support Level | $15.96 | $6.55 |
| Resistance Level | $19.79 | $7.45 |
| Average True Range (ATR) | 0.64 | 0.49 |
| MACD | 0.20 | -0.08 |
| Stochastic Oscillator | 69.23 | 26.89 |
Betterware de Mexico SAPI de CV is a direct-to-consumer selling company. The company operates through two business segments: the home organization products (Betterware segment or BWM segment) and the beauty and personal care products (B and PC) (JAFRA segment). The Betterware's segment is divided in seven categories of the home organization: Kitchen and food preservation, Home solutions, Bedroom, Bathroom, Laundry & Cleaning, Tech & mobility and wellness. The JAFRA's segment is divided into four categories beauty and personal care: fragrance, color (cosmetics), skin care and toiletries. The company generates a majority of its revenue from the Beauty and personal care (B&PC) (JAFRA segment). Geographically, key revenue for the company is derived from Mexico.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.